Avadel Pharmaceuticals plc (AVDL)
USD 8.7
(0.99%)
USD 8.7
(0.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -137.84 Million USD | -39.86% |
| 2022 | -98.56 Million USD | -15.21% |
| 2021 | -85.54 Million USD | -133.34% |
| 2020 | -36.66 Million USD | -117.88% |
| 2019 | -16.82 Million USD | 83.96% |
| 2018 | -104.92 Million USD | -218.83% |
| 2017 | 88.3 Million USD | 1878.45% |
| 2016 | -4.96 Million USD | -106.95% |
| 2015 | 71.44 Million USD | 176.12% |
| 2014 | -93.85 Million USD | -87.59% |
| 2013 | -50.03 Million USD | -1334.84% |
| 2012 | -3.48 Million USD | 63.61% |
| 2011 | -9.58 Million USD | 2.61% |
| 2010 | -9.84 Million USD | 16.28% |
| 2009 | -11.75 Million USD | 41.7% |
| 2008 | -20.16 Million USD | 50.65% |
| 2007 | -40.84 Million USD | -5.18% |
| 2006 | -38.83 Million USD | 4.74% |
| 2005 | -40.76 Million USD | -561.45% |
| 2004 | 8.83 Million USD | 288.02% |
| 2003 | -4.69 Million USD | -2007.17% |
| 2002 | -223 Thousand USD | 92.93% |
| 2001 | -3.15 Million USD | 80.41% |
| 2000 | -16.1 Million USD | -130.1% |
| 1999 | -7 Million USD | 24.66% |
| 1998 | -9.29 Million USD | -3.23% |
| 1997 | -9 Million USD | 0.0% |
| 1996 | -9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -26.03 Million USD | -4.56% |
| 2024 Q2 | -12.74 Million USD | 51.06% |
| 2023 Q2 | -49.54 Million USD | -75.07% |
| 2023 Q1 | -28.29 Million USD | -22.83% |
| 2023 FY | -137.84 Million USD | -39.86% |
| 2023 Q3 | -35.11 Million USD | 29.13% |
| 2023 Q4 | -24.9 Million USD | 29.08% |
| 2022 Q4 | -23.03 Million USD | -35.84% |
| 2022 Q2 | -29.93 Million USD | -4.58% |
| 2022 FY | -98.56 Million USD | -15.21% |
| 2022 Q3 | -16.96 Million USD | 43.35% |
| 2022 Q1 | -28.62 Million USD | -23.73% |
| 2021 FY | -85.54 Million USD | -133.34% |
| 2021 Q1 | -14.81 Million USD | -3.86% |
| 2021 Q2 | -21.93 Million USD | -48.11% |
| 2021 Q4 | -23.13 Million USD | 9.85% |
| 2021 Q3 | -25.66 Million USD | -16.99% |
| 2020 Q2 | 40.26 Million USD | 719.81% |
| 2020 Q1 | -6.49 Million USD | 11.57% |
| 2020 Q3 | -13.69 Million USD | -134.01% |
| 2020 Q4 | -14.26 Million USD | -4.11% |
| 2020 FY | -36.66 Million USD | -117.88% |
| 2019 Q3 | -4.14 Million USD | 6.83% |
| 2019 Q4 | -7.34 Million USD | -77.16% |
| 2019 Q2 | -4.45 Million USD | 45.5% |
| 2019 Q1 | -8.16 Million USD | 89.17% |
| 2019 FY | -16.82 Million USD | 83.96% |
| 2018 Q1 | -12.62 Million USD | -138.88% |
| 2018 FY | -104.92 Million USD | -218.83% |
| 2018 Q2 | -2.78 Million USD | 77.94% |
| 2018 Q3 | -14.09 Million USD | -406.1% |
| 2018 Q4 | -75.42 Million USD | -435.09% |
| 2017 Q2 | 34.12 Million USD | 2.35% |
| 2017 Q1 | 33.34 Million USD | 95.39% |
| 2017 FY | 88.3 Million USD | 1878.45% |
| 2017 Q4 | -5.28 Million USD | -120.24% |
| 2017 Q3 | 26.11 Million USD | -23.47% |
| 2016 Q3 | -16.19 Million USD | -40.26% |
| 2016 Q2 | -11.54 Million USD | -308.28% |
| 2016 Q1 | 5.54 Million USD | -92.79% |
| 2016 FY | -4.96 Million USD | -106.95% |
| 2016 Q4 | 17.06 Million USD | 205.4% |
| 2015 Q3 | -14.47 Million USD | -1130.16% |
| 2015 Q4 | 76.88 Million USD | 631.04% |
| 2015 Q1 | 10.21 Million USD | 131.05% |
| 2015 Q2 | -1.17 Million USD | -111.52% |
| 2015 FY | 71.44 Million USD | 176.12% |
| 2014 Q1 | -24 Million USD | -2517.12% |
| 2014 FY | -93.85 Million USD | -87.59% |
| 2014 Q4 | -32.89 Million USD | -95.59% |
| 2014 Q2 | -20.13 Million USD | 16.11% |
| 2014 Q3 | -16.82 Million USD | 16.47% |
| 2013 Q1 | -9.85 Million USD | -262.26% |
| 2013 FY | -50.03 Million USD | -1334.84% |
| 2013 Q3 | -6.8 Million USD | 80.22% |
| 2013 Q2 | -34.37 Million USD | -248.95% |
| 2013 Q4 | 993 Thousand USD | 114.6% |
| 2012 FY | -3.48 Million USD | 63.61% |
| 2012 Q4 | 6.07 Million USD | 220.5% |
| 2012 Q1 | -46 Thousand USD | 97.98% |
| 2012 Q2 | 213 Thousand USD | 563.04% |
| 2012 Q3 | -5.03 Million USD | -2465.26% |
| 2011 Q3 | 1.24 Million USD | 133.93% |
| 2011 FY | -9.58 Million USD | 2.61% |
| 2011 Q4 | -2.27 Million USD | -283.63% |
| 2011 Q1 | -4.89 Million USD | -339.17% |
| 2011 Q2 | -3.65 Million USD | 25.27% |
| 2010 Q2 | -4.72 Million USD | 12.61% |
| 2010 FY | -9.84 Million USD | 16.28% |
| 2010 Q4 | 2.04 Million USD | 147.99% |
| 2010 Q1 | -5.41 Million USD | -386.09% |
| 2010 Q3 | -4.26 Million USD | 9.87% |
| 2009 Q3 | -5.11 Million USD | 1.71% |
| 2009 FY | -11.75 Million USD | 41.7% |
| 2009 Q4 | -1.11 Million USD | 78.23% |
| 2009 Q1 | -327 Thousand USD | 93.35% |
| 2009 Q2 | -5.2 Million USD | -1490.52% |
| 2008 Q1 | -4.89 Million USD | 39.26% |
| 2008 Q4 | -4.91 Million USD | -6.48% |
| 2008 Q3 | -4.61 Million USD | 19.5% |
| 2008 FY | -20.16 Million USD | 50.65% |
| 2008 Q2 | -5.73 Million USD | -17.14% |
| 2007 Q4 | -8.05 Million USD | 13.01% |
| 2007 Q3 | -9.26 Million USD | 33.86% |
| 2007 Q2 | -14 Million USD | -47.15% |
| 2007 Q1 | -9.51 Million USD | -12.44% |
| 2007 FY | -40.84 Million USD | -5.18% |
| 2006 FY | -38.83 Million USD | 4.74% |
| 2006 Q4 | -8.46 Million USD | 20.46% |
| 2006 Q3 | -10.64 Million USD | -11.05% |
| 2006 Q2 | -9.58 Million USD | 5.5% |
| 2006 Q1 | -10.14 Million USD | 8.55% |
| 2005 Q2 | -9.91 Million USD | -30.82% |
| 2005 Q3 | -12.18 Million USD | -22.84% |
| 2005 FY | -40.76 Million USD | -561.45% |
| 2005 Q1 | -7.58 Million USD | -206.22% |
| 2005 Q4 | -11.09 Million USD | 8.95% |
| 2004 Q1 | 3.78 Million USD | 162.23% |
| 2004 Q2 | -2.08 Million USD | -155.1% |
| 2004 Q4 | 7.13 Million USD | 442.25% |
| 2004 Q3 | -2.08 Million USD | 0.0% |
| 2004 FY | 8.83 Million USD | 288.02% |
| 2003 Q2 | -1.74 Million USD | 27.97% |
| 2003 Q1 | -2.41 Million USD | 30.43% |
| 2003 Q4 | 1.44 Million USD | 172.77% |
| 2003 FY | -4.69 Million USD | -2007.17% |
| 2003 Q3 | -1.98 Million USD | -13.9% |
| 2002 FY | -223 Thousand USD | 92.93% |
| 2002 Q1 | 4.56 Million USD | 139.05% |
| 2002 Q2 | 4.99 Million USD | 9.6% |
| 2002 Q3 | 2.22 Million USD | -55.53% |
| 2002 Q4 | -3.47 Million USD | -256.28% |
| 2001 Q2 | 2.43 Million USD | -29.84% |
| 2001 Q4 | -11.68 Million USD | -544.99% |
| 2001 FY | -3.15 Million USD | 80.41% |
| 2001 Q3 | 2.62 Million USD | 7.89% |
| 2001 Q1 | 3.46 Million USD | 114.39% |
| 2000 Q4 | -24.1 Million USD | -903.57% |
| 2000 Q2 | 2.84 Million USD | 43.39% |
| 2000 Q1 | 1.98 Million USD | 117.97% |
| 2000 FY | -16.1 Million USD | -130.1% |
| 2000 Q3 | 3 Million USD | 5.56% |
| 1999 FY | -7 Million USD | 24.66% |
| 1999 Q4 | -11.03 Million USD | -753.55% |
| 1999 Q3 | 1.68 Million USD | 61.38% |
| 1999 Q2 | 1.04 Million USD | -19.54% |
| 1999 Q1 | 1.3 Million USD | 108.18% |
| 1998 Q2 | 2.7 Million USD | 196.43% |
| 1998 Q3 | 1.7 Million USD | -37.04% |
| 1998 FY | -9.29 Million USD | -3.23% |
| 1998 Q4 | -15.89 Million USD | -1034.76% |
| 1998 Q1 | -2.8 Million USD | 79.56% |
| 1997 Q4 | -13.7 Million USD | -1241.67% |
| 1997 FY | -9 Million USD | 0.0% |
| 1997 Q1 | 2.1 Million USD | 116.54% |
| 1997 Q2 | 1.3 Million USD | -38.1% |
| 1997 Q3 | 1.2 Million USD | -7.69% |
| 1996 Q2 | 900 Thousand USD | 181.82% |
| 1996 Q1 | -1.1 Million USD | 0.0% |
| 1996 Q3 | 700 Thousand USD | -22.22% |
| 1996 Q4 | -12.7 Million USD | -1914.29% |
| 1996 FY | -9 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 11.387% |
| Theratechnologies Inc. | -10.62 Million USD | -1197.158% |
| Safety Shot Inc | -12.18 Million USD | -1031.38% |
| Cosmos Health Inc. | -21.83 Million USD | -531.431% |
| Cronos Group Inc. | -81.37 Million USD | -69.399% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 165.945% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -252.078% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 1200.591% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -3808.643% |
| ProPhase Labs, Inc. | -21.61 Million USD | -537.806% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -2832.334% |
| Dynavax Technologies Corporation | -37.02 Million USD | -272.283% |
| Radius Health, Inc. | -3.92 Million USD | -3412.076% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -5380.601% |
| Alvotech | -354.86 Million USD | 61.154% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -2780.677% |
| Alpha Teknova, Inc. | -35.56 Million USD | -287.619% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 13.51% |
| SCYNEXIS, Inc. | 72.66 Million USD | 289.694% |
| Harrow Health, Inc. | 580 Thousand USD | 23867.069% |
| Biofrontera Inc. | -22.67 Million USD | -507.88% |
| DURECT Corporation | -36.88 Million USD | -273.737% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2516.227% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 393.477% |
| OptiNose, Inc. | -22.74 Million USD | -505.983% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 1191.268% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -812.786% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -2119.498% |
| SIGA Technologies, Inc. | 83.62 Million USD | 264.849% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 1577.323% |
| Shineco, Inc. | -17.06 Million USD | -707.747% |
| Phibro Animal Health Corporation | 53.31 Million USD | 358.556% |
| Procaps Group S.A. | 52.32 Million USD | 363.453% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -1517.377% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -2810.217% |
| Viatris Inc. | 766.2 Million USD | 117.991% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -2780.677% |
| Rockwell Medical, Inc. | -6.67 Million USD | -1966.702% |
| Incannex Healthcare Limited | -30.04 Million USD | -358.87% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -2523.696% |
| Tilray Brands, Inc. | -174.74 Million USD | 21.114% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 182.564% |
| PetIQ, Inc. | 60.01 Million USD | 329.691% |
| Silver Spike Investment Corp. | 7.34 Million USD | 1978.024% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 154.942% |
| Journey Medical Corporation | -2.07 Million USD | -6549.735% |
| Alimera Sciences, Inc. | -1.47 Million USD | -9271.108% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -912.303% |
| Assertio Holdings, Inc. | -243.53 Million USD | 43.397% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -2239.445% |
| Embecta Corp. | 221.5 Million USD | 162.234% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -587.524% |
| Procaps Group, S.A. | 38.97 Million USD | 453.704% |
| PainReform Ltd. | -9.58 Million USD | -1338.324% |
| Hempacco Co., Inc. | -8.81 Million USD | -1464.283% |
| Talphera, Inc. | -16.88 Million USD | -716.206% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 257.227% |
| Alvotech | -354.86 Million USD | 61.154% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 137.804% |
| Kamada Ltd. | 10.06 Million USD | 1469.724% |
| Indivior PLC | -4 Million USD | -3346.225% |
| Currenc Group, Inc. | -6.64 Million USD | -1974.232% |
| Evoke Pharma, Inc. | -7.43 Million USD | -1755.08% |
| Flora Growth Corp. | -50.35 Million USD | -173.76% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -587.524% |
| Evolus, Inc. | -49.23 Million USD | -179.993% |
| HUTCHMED (China) Limited | 18.37 Million USD | 850.199% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 169.979% |
| Akanda Corp. | -10.05 Million USD | -1271.444% |